VolitionRx Partners with Werfen to Develop Diagnostic Test for Antiphospholipid Syndrome
TL;DR
VolitionRx's partnership with Werfen provides exclusive commercial rights to leverage their Nu.Q NETs assay for APS testing, potentially capturing a significant market advantage.
VolitionRx's Nu.Q NETs assay detects neutrophil extracellular traps on Werfen's ACL AcuStar platform to identify thrombosis risk in antiphospholipid syndrome patients through clinical validation.
This collaboration could improve diagnosis and monitoring for 4 million APS patients worldwide, enabling better disease management and potentially saving lives through earlier detection.
VolitionRx's epigenetic technology represents the first CE-IVD biomarker being investigated for APS, offering a novel approach to understanding this complex autoimmune disorder.
Found this article helpful?
Share it with your network and spread the knowledge!
VolitionRx Ltd. has entered into a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center to evaluate the use of Volition's Nu.Q H3.1 Neutrophil Extracellular Traps assay for antiphospholipid syndrome detection. The partnership represents a significant advancement in diagnostic testing for APS, an autoimmune disorder affecting approximately 4 million people globally that is currently diagnosed through two positive antibody tests conducted at least 12 weeks apart.
Gael Forterre, Chief Commercial Officer at Volition, stated that this agreement aligns with the company's strategy to license its proprietary Nu.Q NETs test to major worldwide corporations. The approach leverages partners' disease-specific knowledge, product development capabilities, regulatory experience, and installed base of proprietary analyzers. This collaboration could accelerate the commercialization and widespread adoption of the diagnostic technology.
Marta Palicio, Werfen's Immunoassay Technology Center Innovation R&D Director, confirmed that the Nu.Q NETs assay has already been successfully transferred to Werfen's ACL AcuStar platform. Early results in detecting NETs levels in APS patients have shown promise, prompting further validation and clinical utility studies. These investigations aim to determine the marker's potential role as a thrombosis risk indicator in APS patients, which could lead to improved management of this complex syndrome.
The development is particularly significant because Volition believes its Nu.Q NETs test represents the first CE-IVD biomarker being investigated for APS applications. Current diagnostic methods for APS rely on antibody testing that requires extended waiting periods between tests, potentially delaying diagnosis and treatment. The new assay could streamline the diagnostic process, improve decision-making, and enhance ongoing patient monitoring for better clinical outcomes.
For additional information about Volition's technology and research initiatives, visit https://www.Volition.com. Details about the specialized communications platform covering this development can be found at https://www.BioMedWire.com.
Curated from InvestorBrandNetwork (IBN)
